Ocugen: Clinical Trials

6 trials sponsored by Ocugen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 1 completed, 1 terminated, 1 unknown. 6 Phase 2, 3 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Active not recruiting 3, Completed 1, Terminated 1, Unknown 1
Phase 13Active not recruiting 2, Terminated 1
Phase 32Active not recruiting 1, Unknown 1

Follow Ocugen: new trials by email

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
OCU410ST - Stargardt Disease
Phase 2 / Phase 3Active not recruitingOcugen512023-08-252026-07-31
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
OCU410 - Geographic Atrophy
Phase 1 / Phase 2Active not recruitingOcugen602023-02-232026-10-30
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
BBV152 - COVID-19
Phase 2 / Phase 3UnknownOcugen4002022-02-202023-03-27
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose - Retinitis Pigmentosa, Leber Congenital Amaurosis
Phase 1 / Phase 2Active not recruitingOcugen222022-01-242026-07-31
Dry Eye Disease Study With Brimonidine
Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose - Dry Eye
Phase 2CompletedOcugen842017-09-062022-07-06
Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
Brimonidine 0.15%, Brimonidine 0.075%, Placebo - Dry Eye, Ocular Graft vs Host Disease
Phase 1 / Phase 2TerminatedSandeep Jain, MD152016-05-012019-11-08

Conditions studied

Dry Eye Syndromes (2)  ·  COVID-19 (1)  ·  Enhanced S-Cone Syndrome (1)  ·  Geographic Atrophy (1)  ·  Leber Congenital Amaurosis (1)  ·  Meckel Syndrome, Type 4 (1)  ·  Meibomian Gland Dysfunction (1)  ·  Night Blindness, Congenital Stationary, Autosomal Dominant 1 (1)  ·  Retinitis Pigmentosa (1)  ·  Stargardt Disease (1)

Interventions

Brimonidine Tartrate (2)  ·  BBV152 COVID-19 vaccine (1)  ·  Carboxymethylcellulose Sodium (1)  ·  Lubricant Eye Drops (1)

Countries

United States (6)

Top investigators

Jennifer Henrick, RN, MS (3)  ·  Mohamed Genead, MD (3)  ·  Huma Qamar, MD, MPH, CMI (1)  ·  Sandeep Jain, MD (1)